GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings Estimates

Core Insights - GoodRx Holdings, Inc. reported quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share, representing an earnings surprise of -11.11% [1] - The company posted revenues of $196.03 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.34% [2] - GoodRx shares have declined approximately 28.8% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Performance - Over the last four quarters, GoodRx has not surpassed consensus EPS estimates, with the most recent earnings matching the previous year's figure of $0.08 per share [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.10, with projected revenues of $196.93 million, and for the current fiscal year, the estimate is $0.38 on revenues of $796.43 million [7] Market Outlook - The sustainability of GoodRx's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The Zacks Rank for GoodRx is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical Services industry, to which GoodRx belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, DocGo Inc., is expected to report a quarterly loss of $0.09 per share, reflecting a significant year-over-year decline [9]